Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBM Disclosure Requirements For Rx Switches Likely To Increase Costs – FTC

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation pending in California would likely to discourage generic substitution, thereby increasing consumers’ costs, FTC says. Commission finds that the bill is more likely to undermine competition than promote it.

You may also be interested in...



California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger

Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.

California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger

Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.

PBM Transparency Requirements Needed To Protect Generic Switches – NCPA

A California bill mandating PBM disclosures related to drug substitution should be signed into law, the community pharmacists association says, disputing criticism of the proposal from the Federal Trade Commission. PCMA opposes the measure.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel